Increased Levels of Circulating IL-16 and Apoptosis Markers Are Related to the Activity of Whipple's Disease by Benoit, Marie et al.
Increased Levels of Circulating IL-16 and Apoptosis
Markers Are Related to the Activity of Whipple’s Disease
Marie Benoit, Florence Fenollar, Didier Raoult, Jean-Louis Mege*
Unite ´ des Rickettsies, Centre National de la Recherche Scientifique Unite ´ Mixte de Recherche 6020, Institut Fe ´de ´ratif de Recherche 48, Universite ´ de la
Me ´diterrane ´e, Faculte ´ de Me ´decine, Marseille, France
Background. Whipple’s disease (WD) is an infectious disease caused by Tropheryma whipplei, which replicates in
macrophages and induces the release of interleukin (IL)-16, a substrate of caspase 3, and macrophage apoptosis. The disease is
characterized by intestinal, cardiac or neurological manifestations; its diagnosis is based on invasive analysis requiring tissue
biopsies or cerebrospinal fluid puncture. The disease progression is slow and often complicated by relapses despite empirical
antibiotic treatment. Methodology/Principal findings. We monitored circulating levels of IL-16 and nucleosomes in 36
French patients with WD; among them, some patients were enrolled in a longitudinal follow-up. As compared to control
subjects, the circulating levels of both IL-16 and nucleosomes were increased in untreated patients with WD presenting as
intestinal, cardiac or neurological manifestations. This finding was specific to WD since the circulating levels of IL-16 and
nucleosomes were not increased in patients with unrelated inflammatory diseases such as inflammatory bowel disease or Q
fever endocarditis. We also found that increased levels of IL-16 and nucleosomes were related to the activity of the disease.
Indeed, successful antibiotic treatment decreased those levels down to those of control subjects. In contrast, patients who
suffered from relapses exhibited circulating levels of IL-16 and nucleosomes as high as those of untreated patients.
Conclusions/Significance. Circulating levels of both IL-16 and nucleosomes were increased in WD. This finding provides
simple and non-invasive tools for the diagnosis and the prognosis of WD.
Citation: Benoit M, Fenollar F, Raoult D, Mege J-L (2007) Increased Levels of Circulating IL-16 and Apoptosis Markers Are Related to the Activity of
Whipple’s Disease. PLoS ONE 2(6): e494. doi:10.1371/journal.pone.0000494
INTRODUCTION
Whipple’s disease (WD) is a systemic disease, first described in
1907 by the American pathologist George H. Whipple as an
intestinal lipodystrophy [1]. WD, with fewer than 1,000 cases
reported to date, is considered to be rare although its incidence is
probably underestimated [2]. WD has been traditionally seen as
a gastrointestinal disease characterized by polyarthritis, fatigue,
weight loss, and anemia, followed by a progressive syndrome of
abdominal pain, distension, steatorrhea, and severe cachexia [3].
In about 15% of reported cases, gastrointestinal symptoms are
lacking, and the disease appears as cardiac manifestations such as
myocarditis, pericarditis and negative blood culture endocarditis
[4], or as neurological manifestations including dementia, lethargy
and neurological deficits [5]. The evolution of WD is chronic with
relapses despite empirical antibiotic treatment. The bacterial
etiology of WD was first established in 1961 by the detection of
‘‘bacillary bodies’’ in the intestine of patients [6]. The causative
agent of WD was identified in 1992 as a gram-positive bacterium,
phylogenetically close to the Actinobacter clade as determined by
a molecular approach [7]. In 2000, it was isolated from a patient
with WD and successfully cultured [8]. In 2001, the name of
Tropheryma whipplei was officially ascribed to the WD agent [9], and
the complete sequencing of two strains of T. whipplei was
performed in 2003 [10,11].
The diagnosis of WD has been based for many years on the
presence in intestinal biopsies of large, foamy macrophages
containing periodic acid-Schiff (PAS)-positive inclusions in the
lamina propria, but these PAS-positive inclusions may also be
detected in other tissues [3]. Although the recent development of
molecular tools has improved bacterial detection in tissues [12], the
diagnosis of WD remains invasive [13]. The current treatment is
trimethoprim-sulfamethoxazole given for at least one year [14]. The
antibiotic treatment of WD is empirical and the choice of drug and
the duration of treatment are controversial. The risk of clinical
relapses is high; patients typically have primary or recurrent clinical
manifestations after arrest of treatment, especially those patients
presenting with neurological manifestations [3]. Finally, invasive
investigations arerequired at leastevery six monthsafter diagnosis to
assess the response of patients with WD to antibiotic treatment [3].
In WD, macrophages present in intestinal lesions exhibit an
anti-inflammatory transcriptional profile and a pro-apoptotic
program [15]. In human monocyte-derived macrophages, T.
whipplei stimulates the release of interleukin (IL)-16 that is critical
for bacterial replication, and induces macrophage apoptosis [16].
IL-16 is synthesized as a precursor of 69 kDa, named pro-IL-16,
which is a substrate for caspase 3, the central effector of apoptosis.
The cleavage of pro-IL-16 by caspase 3 releases the biologically
active form of the molecule, which consists of a secreted fragment
of 56 kDa [17]. IL-16 is an immunomodulatory cytokine released
at the inflammatory site. Through its interaction with CD4, IL-16
acts as a chemoattractant for CD4
+ immune cells including T-
cells, monocytes and eosinophils [18]. IL-16-expressing cells
include mononuclear phagocytes [19], CD4
+ [20] and CD8
+ T-
cells [21], eosinophils [22] and mast cells [23]. In preliminary
experiments, we have shown that circulating levels of IL-16 are
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examined whether IL-16 and apoptosis markers were increased in
patients with WD. Increased circulating levels of IL-16 and
nucleosomes were present in patients with WD before the
beginning of their treatment. Antibiotic treatment decreased the
levels of both circulating IL-16 and nucleosomes, whereas patients
who relapsed exhibited similar levels of IL-16 and nucleosomes to
those of untreated patients. We suggest that IL-16 and nucleo-
somes may be useful to assess the prognosis for and the response to
treatment in patients with WD.
METHODS
Patients
Thirty-six French patients with WD (27 men and 9 women) were
included in the study after giving informed consent and receiving
approbation by the Ethics Committee of the Universite ´d el a
Me ´diterrane ´e. The diagnosis was based on clinical features,
histological findings, PCR studies and cultures of tissue samples
[24]. The criteria for confirming the diagnosis of classic Whipple’s
disease and endocarditis due to T. whipplei were previously
described [25,26,27]. The criteria for confirming the diagnosis of
isolated neurological manifestations due to T. whipplei included two
positive PCR assays targeting two different genes performed on
two different cerebrospinal fluid samples. The criteria for
confirming the diagnosis of uveitis due to T. whipplei included
one positive PCR assay targeting two different genes performed on
aqueous humor specimen. For each PCR, positive and negative
controls were used. The features of these patients are detailed in
Table 1. The control groups consisted of healthy subjects (5
women and 8 men), and patients with unrelated diseases. Six
patients with inflammatory bowel disease (3 men with Crohn’s
disease and 3 women with ulcerative colitis) were included. The
diagnosis of inflammatory bowel disease was established by
a combination of clinical evaluation with endoscopic, histological,
radiological, and/or biochemical investigations after exclusion of
enteric infections and ischemia [28]. As controls against infectious
endocarditis, we included in the study 7 patients (3 men and 4
women) with Q fever endocarditis, an endocarditis caused by
Coxiella burnetii, which is an intracellular bacterium that specifically
infects macrophages [29]. The diagnosis of Q fever endocarditis
was based on the modified Duke’s University criteria including the
presence of phase I C. burnetii-specific IgG [30]. Finally, we selected
13 men without WD but with stool or saliva PCR positive for T.
whipplei [31,32], who were presented in the study as asymptomatic.
Determination of circulating IL-16
Blood was collected on EDTA tubes and centrifuged 15 min at
300 g. Plasma was collected and stored at 280uC. Plasma levels of
bioactive IL-16 were measured by ELISA assay (R&D Systems),
according to the manufacturer’s recommendations. The detection
limit was 6.2 pg/ml. The intra- and inter-specific coefficients of
variation ranged from 5 to 10%.
Determination of circulating apoptosis markers
Plasma levels of nucleosomes were measured using an ELISA cell
death detection plus kit (Roche Diagnostics). This assay is based on
a quantitative sandwich enzyme immunoassay that recognizes
DNA and histones [33]. The specific enrichment factor in
nucleosomes, expressed in arbitrary units, was calculated accord-
ing to the manufacturer’s instructions.
Caspase activity was measured with the Apoptosis Detection
Polycaspase Assay Kit (Immunochemistry Technologies), accord-
ing to the manufacturer’s protocol. The assay is based on
a Fluorochrome Inhibitor of Caspases (FLICA) that binds
covalently active caspases in the cells. Briefly, 100 ml of whole
blood were incubated in 96-wells with 5 mL of 30X FLICA
solution for 1 h at room temperature and washed twice. Red blood
cells were then lyzed with 150 mM ammonium chloride for
10 min under agitation. Leukocytes were centrifuged 10 min at
400 g, washed twice, fixed and analyzed by flow cytometry (EPICS
XL, Coulter). Gating was performed using forward and side
scatter to remove dead cells and remaining red blood cells from
Table 1. Epidemiological and clinical features of patients with WD
..................................................................................................................................................
Presentations of
Whipple’s disease Males/females
Age Mean
[Range] Diagnosis Main clinical manifestations
Classical Whipple’s
disease
15/9 62 [35–78] PAS
+,I H C
+ and PCR
+ on duodenal biopsies Diarrhea, arthralgia, fever, WL, AP,
adenopathy, pleuritis, asthenia, myalgia,
ascitis, pigmentation
48 [33–73]
Endocarditis due to
T. whipplei
5/0 60 [51–67] PAS
+,I H C
+ and PCR
+ on cardiac valves Arthralgia, WL, dyspnea, arterial
embolus, and/or stroke
PAS
2,I H C
2 and PCR
2 on duodenal biopsies
Isolated neurological
manifestations due to
T. whipplei
6/0 47 [36–59] PCR
+ on cerebrospinal fluid for all patients WL, asthenia, cognitive troubles,
myoclonus, personality changes, and/or
hypothalamic manifestations
PCR
+ and PAS
+ on brain biopsy for one patient
PCR
+ on stools for two patients
PCR
+ on saliva for one patient
PAS
2,I H C
2 and PCR
2 on duodenal biopsies
Uveitis due to T. whipplei 1/0 80 PCR
+ on aqueous humor Uveitis
PCR
+ on stools
PAS
2,I H C
2 and PCR
2 on duodenal biopsies
Footnotes: PAS=Periodic acid-Schiff staining, IHC=Immunohistochemistry performed using polyclonal rabbit anti-T. whipplei antibodies, PCR=Polymerase chain
reaction, WL=Weight Loss, AP Abdominal Pain
doi:10.1371/journal.pone.0000494.t001
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The percentage of leukocytes with active caspases was determined
using the Expo32 ADC software.
Statistical analysis
Results were expressed as individual values with medians. Quanti-
tative data were compared with the non-parametric Mann-Whitney
U test. Differences were considered significant at p,0.05. The levels
of sensitivity (Se) and specificity (Sp) were calculated manually: Se=
(TP/(TP+FN)) and Sp=(TN/(TN+FP)), where TP: True Positives,
FN: False Negatives, TN: True Negatives, and FP: False Positives.
RESULTS
Circulating IL-16 and apoptosis markers in untreated
patients with WD
Since the bacteriological diagnosis of WD in France is established in
our laboratory, the frozen plasma of individualssuspected of WD was
collected over a 3-year period. Only plasmas from patients with
confirmed WD were subsequently analyzed for the presence of IL-16
and nucleosomes. Some patients were seen in Marseille by our
medical staff, which allowed for leukocyte study and the longitudinal
follow-up ofthese patients.In untreated patientswithWD, circulating
levels of IL-16 were significantly (p,0.001) increased as compared to
asymptomatic subjects and control subjects (Fig 1A). The apoptosis
was investigated by measuring circulating nucleosomes and caspase
activity in leukocytes. Circulating nucleosomes were significantly
(p,0.001) increased in untreated patients with WD as compared to
asymptomatic subjects and control subjects (Fig 1B). Circulating IL-
16 and nucleosomes were related in untreated patients with WD
(y=125.73x+246.71, correlation coefficient R2=0.71) but were not
related in asymptomatic subjects (y=27.35x+344.60, R2=0.03) or
control subjects (y=0.75x+
280.02, R2=0.01) (Fig 1C).In addition, we collected leukocytes of 15
untreated patients with WD. Active caspases in leukocytes were
significantly higher (p,0.001) in untreated patients with WD
(13.261.0%) than in asymptomatic subjects (6.161.0%) or control
subjects (4.560.7%) (Fig 1D).
Although untreated patients with WD exhibited high circulating
levels of IL-16 and nucleosomes, there was some heterogeneity in
patients. As WD is characterized by different intestinal, cardiac or
neurological manifestations, we asked if the levels of IL-16 and
nucleosomes were related to the clinical manifestations of WD.
Circulating levels of IL-16 and nucleosomes were similarly increased
in patients with intestinal (Fig 2A and B), cardiac and neurological
manifestations (Fig 2C and D). Increased levels of both IL-16 and
nucleosomes were specific to WD. Indeed, untreated patients with
intestinal manifestations of WD exhibited significantly higher
circulating levels of IL-16 than patients with ulcerative colitis
(p,0.05) or Crohn’s disease (p,0.01) (Fig 2A). Circulating
nucleosomes were significantly (p,0.05) higher in untreated patients
with intestinal manifestations of WD as compared to patients with
Crohn’s disease (Fig 2B). In contrast, patients with ulcerative colitis
exhibited significantly higher levels of circulating nucleosomes than
untreated patients with intestinal manifestations of WD (p,0.01) or
Crohn’s disease (p,0.05) (Fig. 2B). As compared to the infective
endocarditis due to C. burnetii, untreated patients with endocarditis
due to T. whipplei exhibited significantly (p,0.01) higher levels of
circulating IL-16 (Fig. 2C) and nucleosomes (Fig 2D). Taken
together, these results show that high circulating levels of both IL-16
and nucleosomes characterized untreated patients with WD.
Figure 1. Circulating IL-16 and apoptosis markers in untreated WD patients. A and B, The circulating levels of IL-16 (A) and nucleosomes (B) were
determined by immunoassays in control subjects, asymptomatic subjects and patients with WD. Results are expressed as individual values with
medians. C, Correlation between circulating levels of IL-16 and nucleosomes in control subjects, asymptomatic subjects and patients with WD. Dots
were analyzed by linear regression. D, The caspase activity in leukocytes (FLICA measurement) was analyzed by flow cytometry. Results are expressed
as the percentage of leukocytes that expressed active caspases.
doi:10.1371/journal.pone.0000494.g001
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WD, we tested the value of IL-16 and nucleosomes for diagnosis of
WD in this small sampling. Using a cut-off of 500 pg/ml for IL-16,
the sensitivity of the test to detect active WD was 80% (16/20
samples) and the specificity was 85% (23/27 samples). Using a cut-
off of 1,000 pg/ml, these values were 45% (10/22 samples) and
96% (26/27 samples), respectively. For nucleosomes, a cut-off of 3
mU led to a sensitivity of 76% (16/21 samples) and a specificity of
89% (24/27 samples). A cut-off of 6 mU led to a sensitivity of 52%
(11/21 samples) and a specificity of 100% (27/27 samples). Using
the combination of the two parameters, a cut-off of 500 pg/ml for
IL-16 and of 3 mU for nucleosomes led to a sensitivity of 80%
(16/20 samples) and a specificity of 96% (26/27 samples). Using
a cut-off of 1,000 pg/ml for IL-16 and of 6 mU for nucleosomes,
the sensitivity was 50% (9/18 samples) and the specificity was
100% (27/27 samples).
Circulating IL-16 and nucleosomes in treated WD
patients
To determine if high levels of IL-16 and nucleosomes are related to
active WD, we monitored circulating IL-16 and nucleosomes in 26
patients treated with antibiotics and in 8 patients with relapses
despite antibiotic treatment. Antibiotic treatment decreased the
circulating levels of IL-16 (Fig. 3A) and nucleosomes (Fig. 3B) in
patients down to levels comparable to those found in control
subjects, independently of the clinical manifestations of WD. In
relapsing patients with intestinal or neurological manifestations of
WD,thecirculatinglevelsofIL-16(Fig3A)andnucleosomes(Fig3B)
were high and similar to those found in untreated patients with WD.
Finally, we regularly monitored 2 patients with neurological
manifestations of WD who suffered from relapses after arrest of
their antibiotic treatment.The first patient exhibited low levelsof IL-
16 and nucleosomes during the total duration of his treatment; few
months after the arrest of his treatment, he presented clinical
symptoms of relapses, and both circulating IL-16 and nucleosomes
were increased (Fig 3C). The second patient presented 2 relapses.
The levels of circulating IL-16 and nucleosomes were transiently
increased during the clinical relapses, and decreased when clinical
symptoms disappeared after newly designed antibiotic therapy
(Fig 3D). These results demonstrate that antibiotic treatment of
patients with WD decreased circulating levels of IL-16 and
nucleosomes whereas relapses were associated with high levels of
IL-16 and nucleosomes, suggesting that circulating IL-16 and
nucleosomes may be used as markers of active WD.
DISCUSSION
We show here that systemic IL-16 is related to WD. While
increased IL-16 has been reported in local lesions of chronic
immune diseases, including allergen-induced bronchial asthma
and rheumatoid arthritis [34] and in the mucosa of patients with
inflammatory bowel disease, including ulcerative colitis and
Crohn’s disease [35,36], the systemic role of IL-16 is a new
finding. Indeed, circulating levels of IL-16 were not increased in
patients with ulcerative colitis or Crohn’s disease even though IL-
16 is expressed in tissue lesions. Conversely, circulating IL-16 was
increased in patients with WD (our results) and is produced by
macrophages isolated from blood [16], but the expression of IL-16
is not increased in macrophages infiltrating intestinal lesions of one
patient with WD [15], suggesting that IL-16 is associated with the
systemic phase of WD. The presence of high circulating levels of
IL-16 in WD could not be explained by the production of IL-16 by
Figure 2. Clinical manifestations and circulating IL-16 and apoptosis markers. A and B, Circulating levels of IL-16 (A) and nucleosomes (B) in
untreated patients with intestinal manifestations of WD, ulcerative colitis and Crohn’s disease. C and D, Circulating levels of IL-16 (C) and nucleosomes
(D) in untreated patients with cardiac (Endo WD) or neurological manifestations of WD, and Q fever endocarditis (Endo QF). Results are expressed as
individual values with medians.
doi:10.1371/journal.pone.0000494.g002
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cell types as a source for IL-16. Indeed, some patients with WD
exhibited a high number of eosinophils [2], known to produce IL-
16 [22], but the patients with hypereosinophilia did not exhibit
higher levels of IL-16 (data not shown).
We also showed that systemic IL-16 was associated with
apoptosis in WD. We previously reported that T. whipplei
persistence is associated with the up-regulated expression of pro-
apoptotic genes in vitro [16] and in vivo [15]. Since IL-16 was
more prevalent in blood from patients with WD, we studied those
patients’ circulating levels of nucleosomes, which result from DNA
fragmentation in the late stages of apoptosis. Circulating levels of
nucleosomes were increased in untreated patients with WD and
correlated with increased caspase activity in leukocytes. In
addition, circulating levels of nucleosomes were correlated to
those of IL-16, suggesting a clear-cut relationship between these
markers. This finding may be related to the fact that IL-16 is
a substrate of caspase 3, an effector of the apoptotic pathway.
Increased circulating levels of IL-16 and nucleosomes were
specific to WD. Indeed, patients with ulcerative colitis exhibited
very high levels of circulating nucleosomes as compared to patients
with WD, but their circulating levels of IL-16 were similar to those
of healthy controls. In contrast, patients with Crohn’s disease or
with Q fever endocarditis had low levels of IL-16 and nucleo-
somes. The combination of increased levels of IL-16 and caspase 3
activity has been reported in cerebrospinal fluid from patients with
multiple sclerosis and experimental autoimmune encephalomyeli-
tis, and is correlated with disease activity [37,38]. Increased serum
levels of IL-16 have been associated with atopic dermatitis in
children, but are not correlated with severity of the disease [39]. In
addition, increased circulating levels of IL-16 and nucleosomes
were specific to WD disease, not to the T. whipplei infection.
Indeed, subjects which were PCR positive for T. whipplei in their
stool and saliva but who lacked clinical manifestations did not
exhibit increased levels of IL-16 and nucleosomes. In a random
sample of 40 healthy individuals, 35% showed evidence of T.
whipplei DNA in their saliva [32]. T. whipplei DNA was found in
13% of duodenal biopsies or the gastric juice of 105 patients
having elective gastroscopy, with no clinical signs of WD [31]. The
detection of T. whipplei DNA on repeated samples suggests that T.
whipplei may be an oral commensal organism that is ubiquitous and
generally not pathogenic [40]. Using a rather small number of
patients with active WD, we found that the sensitivity and the
specificity of measurements of circulating IL-16 and nucleosomes
have a good value for the diagnosis of active WD. However, the
tested samples are small and these results, although encouraging,
should be considered preliminary. It is likely that increased levels
of circulating IL-16 and nucleosomes in patients with WD are
a hallmark of the disease and can permit doctors to discriminate
between subjects with WD and healthy carriers.
Finally, high levels of circulating IL-16 and nucleosomes were
related to the activity of WD because the successful antibiotic
treatment decreased both markers in patients with WD. Antibiotic
therapy leads to a rapid improvement in the clinical status of the
majority of patients with WD [41]. Diarrhea and fever can resolve
within 1 week of the start of therapy, arthropathy and other
symptoms improve after a few weeks, and a normalization of
laboratory findings is observed within a few months in most
patients [3]. However, these patients are followed by analysis of
cerebrospinal fluid or duodenal biopsies 6 months and 12 months
Figure 3. Effect of antibiotic treatment on circulating levels of IL-16 and nucleosomes. A and B, Circulating levels of IL-16 (A) and nucleosomes (B)
in patients successfully treated and patients who suffered from relapses. C and D, Time course of circulating IL-16 (¤) and nucleosomes (%) in two
patients with neurological manifestations of WD who suffered from relapses. q represents the date of clinical relapses.
doi:10.1371/journal.pone.0000494.g003
IL-16 and Apoptosis
PLoS ONE | www.plosone.org 5 June 2007 | Issue 6 | e494after diagnosis. Antibiotic treatment is generally stopped when
PCR for T. whipplei and PAS staining are negative [3]. In some
patients, the persistent bacterial infection of tissues results in
relapses. The current follow-up for these patients consists of
analysis of the cerebrospinal fluid or intestinal biopsies every
6 months until bacterial material is undetectable, which can
require several years [2]. Patients with relapses exhibited levels of
circulating IL-16 and nucleosomes as high as those of untreated
patients. We suggest that the dosage of circulating levels of IL-16
and nucleosomes together with simple, rapid and non-invasive
tests may be useful to check the efficiency of the antibiotic
treatment and the occurrence of relapses in patients with WD.
In conclusion, persistent levels of circulating IL-16 and
apoptosis markers were specifically associated with active WD,
whatever the clinical manifestations of the disease. These levels
and markers may provide simple and non-invasive tools for the
diagnosis of and the prognosis for WD. Our results also suggest
that anti-IL-16 therapy could be administered along with
antibiotic treatment for patients with WD, as successfully reported
in experimental autoimmune encephalomyelitis [42].
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